IO Biotech (IOBT) entered into a loan facility of up to EUR 57.5M from the European Investment Bank. The debt facility includes three committed tranches totaling up to EUR 37.5M, which will become available if the company satisfies certain conditions, and one uncommitted accordion tranche of EUR 20M. The company expects the first two tranches to be available for disbursement in the first quarter of 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IOBT:
- IO Biotech reports Q3 EPS (36c), consensus (29c)
- IO Biotech sees cash runway into 4Q25
- IO Biotech reports data on IO102-IO103 vaccine in combination with KEYTRUDA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
